Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 5/20 | 0.72 |
| ▸ | P2RX1 | P51575 | 11/20 | 0.66 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.65 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.65 |
| ▸ | TMPRSS4 | Q9NRS4 | 9/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | IKBKB | O14920 | 1/20 | 0.56 |
| ▸ | CHUK | O15111 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MYLK | Q15746 | 1/20 | 0.56 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30472735 | 0.84 | TMPRSS4 (0.74) | KCNMA1P2RX1P2RX4P2RX7TMPRSS4 | |
| SCHEMBL27786748 | 0.84 | KCNMA1 (1.00) | KCNMA1P2RX1P2RX4P2RX7TMPRSS4 | |
| SCHEMBL30472727 | 0.83 | TMPRSS4 (0.64) | KCNMA1P2RX1P2RX4P2RX7TMPRSS4 | |
| SCHEMBL30503640 | 0.82 | P2RX1 (0.68) | KCNMA1P2RX1P2RX4P2RX7TMPRSS4 | |
| SCHEMBL17770404 | 0.82 | P2RX1 (0.68) | KCNMA1P2RX1P2RX4P2RX7TMPRSS4 | |
| SCHEMBL28577332 | 0.81 | TMPRSS4 (0.67) | KCNMA1P2RX1P2RX4P2RX7TMPRSS4 | |
| SCHEMBL30216760 | 0.81 | TMPRSS4 (0.67) | KCNMA1P2RX1P2RX4P2RX7TMPRSS4 | |
| SCHEMBL30503655 | 0.80 | P2RX1 (0.62) | KCNMA1P2RX1P2RX4P2RX7TMPRSS4 | |
| SCHEMBL30503653 | 0.80 | P2RX1 (0.62) | KCNMA1P2RX1P2RX4P2RX7TMPRSS4 | |
| SCHEMBL29024721 | 0.80 | P2RX1 (0.62) | KCNMA1P2RX1P2RX4P2RX7TMPRSS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | claimed |
| US-9266872-B2 | 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2016-02-23 | — | — | US | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| WO-2013058613-A2 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | 한국생명공학연구원 (KR) | 2013-04-25 | — | — | WO | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| CN-101849953-B | Inflammatory cytokine release inhibitor | INST MED MOLECULAR DESIGN INC | 2012-04-25 | — | — | CN | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| CN-100370975-C | Inflammatory cytokine production dissociation inhibitor | INST OF MEDICINE MOLECULAR DES (JP) | 2008-02-27 | — | — | CN | disclosed |
| CN-101125138-A | Inhibitors against the production and release of inflammatory cytokines | INST MED MOLECULAR DESIGN INC (JP) | 2008-02-20 | — | — | CN | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| CN-1489458-A | Inflammatory cytokine production dissociation inhibitor | ��ʽ����ҽҩ��������о��� | 2004-04-14 | — | — | CN | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | KCNMA1 3082/4885P2RX1 1459/4885P2RX4 2669/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | KCNMA1 3380/4885P2RX1 1538/4885P2RX4 2695/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | KCNMA1 3380/4885P2RX1 1538/4885P2RX4 2695/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | KCNMA1 3380/4885P2RX1 1538/4885P2RX4 2695/4885 |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | TMPRSS2, TMPRSS4, PRSS2 | KCNMA1 4136/4885P2RX1 4273/4885P2RX4 3330/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | KCNMA1 2705/4885P2RX1 2316/4885P2RX4 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.